Scholarlink

Background <p>Colorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.</p> Methods <p>We analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.</p> Results <p>Our findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.</p> Conclusions <p>This research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management

  • 期刊论文

  • 发表日期：

    2025年2月19日

查看全文
  • Mohammad Taghizadeh-Teymorloei,
  • Vahid Jafarlou,
  • Somaieh Matin,
  • Mortaza Raeisi,
  • Yousef Roosta,
  • Sima Mansouri-Derakhshani,
  • Abbas Ali Hosseinpour Feizi,
  • Abbas Karimi

摘要

Background

Colorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.

Methods

We analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.

Results

Our findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.

Conclusions

This research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.

Graphical abstract